Main Street Financial Solutions LLC Has $301,000 Stock Position in Urogen Pharma $URGN

Main Street Financial Solutions LLC lessened its stake in shares of Urogen Pharma (NASDAQ:URGN) by 61.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,190 shares of the company’s stock after selling 12,800 shares during the period. Main Street Financial Solutions LLC’s holdings in Urogen Pharma were worth $301,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Paradigm Biocapital Advisors LP grew its stake in Urogen Pharma by 6.1% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company’s stock valued at $104,773,000 after purchasing an additional 257,564 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Urogen Pharma during the 2nd quarter worth approximately $117,814,000. Morgan Stanley raised its stake in shares of Urogen Pharma by 1.4% during the 4th quarter. Morgan Stanley now owns 2,562,901 shares of the company’s stock worth $60,023,000 after purchasing an additional 34,455 shares in the last quarter. Soleus Capital Management L.P. acquired a new stake in shares of Urogen Pharma in the 2nd quarter valued at approximately $29,934,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Urogen Pharma by 20.3% in the 1st quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock valued at $29,808,000 after buying an additional 280,199 shares during the last quarter. Institutional investors own 91.29% of the company’s stock.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the transaction, the insider directly owned 119,763 shares of the company’s stock, valued at $4,790,520. This represents a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 25,222 shares of company stock valued at $892,661. 4.80% of the stock is owned by corporate insiders.

Urogen Pharma Trading Down 0.4%

URGN opened at $48.92 on Wednesday. Urogen Pharma has a 1-year low of $15.86 and a 1-year high of $49.67. The stock’s fifty day simple moving average is $39.38 and its 200 day simple moving average is $28.55. The stock has a market cap of $2.39 billion, a PE ratio of -24.71 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $72.46 million for the quarter, compared to analysts’ expectations of $63.55 million. Equities analysts forecast that Urogen Pharma will post -0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on URGN. Guggenheim raised their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Oppenheimer upped their price target on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Friday, July 17th. Finally, Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.38.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.